Related Experiment Videos
[Potential possibilities of using adrenergic beta blockers in chronic heart failure]
Insights
Beta-blockers significantly improved heart function in chronic heart failure patients resistant to other treatments. Key predictors of beta-blocker efficacy include disease duration and left ventricular ejection fraction.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Chronic heart failure (CHF) poses a significant clinical challenge, often requiring multifaceted treatment approaches.
- Patients resistant to standard therapies like cardiac glycosides, diuretics, and vasodilators need alternative management strategies.
Purpose of the Study:
- To evaluate the efficacy of beta-adrenoblocker (beta-blocker) therapy in patients with chronic heart failure.
- To identify predictors influencing the effectiveness of beta-blockers in this patient cohort.
Main Methods:
- A study involving 26 patients with CHF of various etiologies (coronary heart disease, rheumatic heart disease, dilated cardiomyopathy, chronic myocarditis).
- Beta-blockers (oxprenolol, propranolol, metoprolol) were added to existing treatments for patients refractory to conventional therapies.
- Functional class was assessed using the New York Heart Association (NYHA) classification system.
Main Results:
- Significant improvement in NYHA functional class from 3.67 ± 0.1 to 2.29 ± 0.1 was observed with beta-blocker therapy.
- Identified predictors of beta-blocker efficacy included disease duration, diastolic blood pressure, cardiac rhythm, and left ventricular ejection fraction.
Conclusions:
- Beta-blockers represent a valuable therapeutic option for patients with chronic heart failure who are resistant to standard treatments.
- Understanding the predictors of efficacy can help optimize beta-blocker selection and management in CHF patients.
Abstract:
The study was undertaken to examine the efficacy of beta-adrenoblockers used in 26 patients with chronic heart failure which had been caused by coronary heart disease in 12 patients, by rheumatic heart disease in 8 patients, by dilated cardiomyopathy in 5 patients, and by chronic myocarditis in 1 patient. beta-Blockers such as oxprenolol, propranolol, and metoprolol were supplemented to the therapy of the patients with chronic heart failure who were resistant to cardiac glycosides, diuretics, and vasodilators. This resulted in functional class improvement by the New York Heart Association from 3.67 +/- 0.1 to 2.29 +/- 0.1. The authors defined the following predictors of the efficacy of beta-blockers in chronic heart failure: duration of the disease, diastolic pressure, cardiac rhythm, and left ventricular ejection fraction and discussed the mechanisms responsible for their positive effect in chronic heart failure.